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Background: The minor allele (C) of the single-nucleotide polymorphism (SNP)
rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been
associated with an increased likelihood of treatment success with metformin in type 2
diabetes. We herein investigated whether the same SNP would predict clinical response
to neoadjuvant metformin in women with early breast cancer (BC).
Methods: DNA was collected from 79 patients included in the intention-to-treat
population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients
randomized to receive either metformin combined with anthracycline/taxane-based
chemotherapy and trastuzumab or equivalent regimenwithout metformin, before surgery.
SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative
polymerase chain reaction.
Cuyàs et al. ATM SNP rs11212617 and Anti-cancer Metformin
Results: Logistic regression analyses revealed a significant relationship between the
rs11212617 genotype and the ability of treatment arms to achieve a pathological
complete response (pCR) in patients (odds ratio [OR]genotype×arm = 10.33, 95%
confidence interval [CI]: 1.29–82.89, p = 0.028). In the metformin-containing arm,
patients bearing the rs11212617 C allele had a significantly higher probability
of pCR (ORA/C,C/C = 7.94, 95%CI: 1.60–39.42, p = 0.011). Conversely, no
association was found between rs11212617 and clinical response in the reference arm
(ORA/C,C/C = 0.77, 95%CI: 0.20–2.92, p = 0.700). After controlling for tumor size and
hormone receptor status, the rs11212617 C allele remained a significant predictor of
pCR solely in the metformin-containing arm.
Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as
a predictive clinical biomarker to inform the personalized use of metformin in BC patients.
Trial Registration: EU Clinical Trials Register, EudraCT number 2011-000490-30.
Registered 28 February 2011, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-
000490-30/ES.
Keywords: metformin, breast cancer, neoadjuvancy, HER2, ATM, rs11212617
INTRODUCTION
The minor allele C of the noncoding single nucleotide
polymorphism (SNP) rs11212617, which is located near the
ataxia telangiectasia mutated (ATM) gene, was found to
be associated with the metabolic response to the biguanide
metformin in the first genome-wide association study (GWAS)
carried out in 3,912 Europeans with type 2 diabetes (T2D) (1).
Although lack of replication occurred in some studies aiming
to verify the association between rs11212617 and the effect of
metformin in multiple ethnic groups (2), a meta-analysis in
smaller cohorts suggested that the rs11212617 C allele might be
considered as the first robustly replicated common susceptibility
locus associated with metformin treatment success in patients
with T2D (3). Moreover, rs11212617 remained a top signal with
no other genome-significant hits in a more recent GWAS of
13,123 participants of different ancestries, but failed to associate
with glycemic response to metformin in a systematic three-
stage replication study (4). However, rs11212617 has recently
been shown to significantly affect not only the response to
metformin in terms of insulin Z score, but also metformin
plasma concentration (5). Mechanistic studies have shown that
rs11212617 increases enhancer activity and could lead to elevated
expression of several target genes including ATM itself (6). Yet,
almost nothing is known about the impact of the rs11212617 C
allele on the clinical efficacy of metformin in several ongoing
clinical trials aiming to evaluate its potential benefits in a cancer
setting (7).
A potential anti-cancer effect of metformin has gained
considerable epidemiological and pre-clinical support over
the last decade (7–10). First, a large number of population-
based observational and cohort studies have suggested a
cancer-preventive advantage associated with metformin usage
among T2D patients (11). Second, diabetic patients with breast
cancer receiving metformin during neoadjuvant chemotherapy
were reported to benefit from a 3-fold greater pathological
complete response (pCR) when compared with those who
did not receive metformin (12). Third, an ever-growing
number of pre-clinical studies have proposed numerous
cell-autonomous (e.g., AMPK/mTOR-related) and non-cell-
autonomous (e.g., insulin/IGF-1-related) molecular mechanisms
that have enthusiastically endorsed the clinical development
of metformin as a novel anti-cancer drug (13–15). However,
one should acknowledge that a metformin-driven cancer-
preventive advantage does not necessarily imply an effective
therapeutic efficacy in non-diabetic patients with established
cancers, and it remains unclear whether the adjuvant use
of metformin in combination with standard cancer therapy
could translate into better clinical outcomes (16–19). Indeed,
recent randomized studies reporting the use of metformin in
cancer treatment have yielded mixed results in patients with
advanced disease (20, 21). Although the results of much larger
randomized studies, such as NCIC CTG MA.32, the most
advanced adjuvant trial investigating the effects of metformin
vs. placebo on invasive disease-free survival and other outcomes
on early breast cancer in 3,649 women (22), will be of great
interest to confirm or reject the causal nature of the suggested
correlation between metformin use and survival benefit in
cancer patients, it is also true that companion biomarker
studies are urgently needed to refine tumor and patient
selection when using metformin as an adjuvant to established
cancer therapeutics.
We herein investigated whether the presence of the
rs11212617 C allele could predict the pathological complete
response (pCR) in the METTEN study (23, 24), a randomized,
open-label, multicenter, phase 2 trial of neoadjuvant metformin
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in combination with trastuzumab and chemotherapy in women
with early HER2-positive breast cancer.
MATERIALS AND METHODS
Subjects
The METTEN study was registered with the EU Clinical
Trials Register and is available online (https://www.
clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES).
Patients were randomly assigned to receive daily metformin
(850mg twice-daily) for 24 weeks concurrently with 12 cycles
of weekly paclitaxel (80 mg/m2) plus trastuzumab (4 mg/kg
loading dose followed by 2 mg/kg) followed by four cycles of
3 weekly fluorouracil (600 mg/m2), epirubicin (75 mg/m2),
cyclophosphamide (600 mg/m2) with concomitant trastuzumab
(6 mg/kg) (arm A), or equivalent sequential chemotherapy
plus trastuzumab without metformin (arm B), followed by
surgery. Patients had surgery within 4–5 weeks of the last cycle
of neoadjuvant treatment (24). Post-surgery, patients received
thrice-weekly trastuzumab to complete 1 year of neoadjuvant-
adjuvant therapy. Genotyping of SNP rs11212617 was carried
out in the intention-to-treat (ITT) population (n = 79), which
included all randomly assigned patients who received at least one
dose of study medication.
Assessment of Pathological Complete
Response (pCR)
pCR was defined as absence of invasive tumor cells on
hematoxylin and eosin evaluation of the complete resected
breast specimen (and all sample regional lymph nodes if
lymphadenectomy was performed) following the completion of
neoadjuvant systemic therapy. Residual ductal carcinoma in situ
(DCIS) only was included in the definition of pCR (ypT0/is,
ypN0) (24).
Analytical Methods
Blood was drawn after an overnight fast. Serum glucose was
measured in duplicate using the glucose oxidase method and
serum insulin was measured in duplicate using the Human
Insulin ELISA (Cat. # EZHI-14K, Merck Millipore, Billerica,
MA). The lowest level of insulin that can be detected by this
assay is 2 µU/mL when using a 20 µL sample size. Intra-
and inter-assay coefficients of variation were below 6 and 11%,
respectively. Fasting insulin resistance was calculated using the
homeostasis model assessment (HOMA) using the following
formula: HOMA-IR = fasting glucose (mmol/L) × fasting
insulin (mU/L)/22.5.
Genotyping of SNP rs11212617
The ATM rs11212617 SNP variants were determined using
the 5
′
exonuclease TaqMan-based allelic discrimination method
(Applied Biosystems, assay ID C_134213_10).
Statistical Analysis
Descriptive data were summarized using percentages, medians or
means with their respective 25 and 75 percentiles or standard
deviations as appropriate. Clinical baseline characteristics
between groups (non-pCR and pCR) were assessed using Chi-
square or Fisher’s exact test for categorical variables, student t-
test for continuous variables with normal distribution, or Mann-
Whitney U test for non-normal distributions. The assumption of
normality was evaluated with the Shapiro-Wilk test. Changes in
glucose, insulin, and HOMA-IR between pre and post treatment
were compared using the Wilcoxon test. The R package Hardy-
Weinberg (http://www.jstatsoft.org/v64/i03/) was employed to
check whether the Hardy-Weinberg equilibrium holds among
study population. Binary logistic regression was used to assess
the prognostic effect of baseline rs11212617 genotype on pCR.
Unadjusted and adjusted odds ratios (ORs) with their relative
95% confidence intervals (CIs) were reported as a measure
of association. All tests were 2- sided and P ≤ 0.05 was set
as statistically significant. Statistical analyses were carried out
using SPSS (IBM Corp. released 2017. IBM SPSS Statistics for
Windows, Version 25.0; Armonk, NY) and STATA (StataCorp.




This study was designed to evaluate the clinical relevance
of the SNP rs11212617 C allele with respect to its potential
to predict a pCR in breast cancer patients with HER2
overexpression treated with metformin-containing neoadjuvant
systemic therapy (Figure 1). We conducted the study with
patients belonging to the ITT population of the METTEN trial,
which included all randomly assigned patients who received at
least one dose of study medication (n = 79) (24). A flowchart
describing the formation of each cohort in the study is shown
in Figure 1. The baseline characteristics of those ITT patients
who achieved pCR after neoadjuvant therapy and those who
did not are shown in Table 1. The comparison of clinical-
pathological variables at diagnosis between patients of each non-
pCR/pCR cohort revealed no significant differences, except for
hormone receptor status. The non-pCR group tended to have
more estrogen receptor-negative and/or progesterone-positive
tumors (p= 0.056).
Allele Frequencies of rs11212617
The rs11212617 polymorphism was evaluable in most of the
patient samples, and 70 of 79 patients (89%) were genotyped
(Figure 1,Table 2). TheA and C allelic frequencies of rs11212617
in our patients were 69 and 31%, respectively. The frequencies
of three genotypes in all the patients were 14.3% (C/C), 32.9%
(A/C), and 52.9% (A/A). These genotype frequencies were very
similar to those predicted by the Ensembl genome database
for a Tuscany, in Italy (TSI) population, and slightly different
to those observed in Europeans and the Iberian population in
Spain (Table 2). Despite the small population size, there was no
significant deviation in rs11212617 genotype frequencies in our
population from the Hardy-Weinberg expectation [HWE; Sum
Equally Likely or More Extreme [SELOME] p = 0.0879]. No
significant differences were observed in the genotype frequencies
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FIGURE 1 | The METTEN study. (Top) The open-label, multicenter, phase II randomized METTEN study was designed to evaluate the clinical activity, tolerability, and
safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in operable, locally advanced, or inflammatory HER2-positive BC (23, 24). Women with
primary, non-metastatic HER2-positive BC were randomly assigned (1:1) to receive daily metformin (850mg twice-daily) for 24 weeks concurrently with 12 cycles of
weekly paclitaxel plus trastuzumab followed by four cycles of 3 weekly fluorouracil, epirubicin, cyclophosphamide plus trastuzumab (arm A) or equivalent sequential
chemotherapy plus trastuzumab without metformin (arm B), followed by surgery. The primary end point was pCR, defined as absence of invasive tumor cells on
hematoxylin and eosin evaluation of the complete resected breast specimen (and all sample regional lymph nodes if lymphadenectomy was performed) following the
completion of neoadjuvant systemic therapy. Residual ductal carcinoma in situ (DCIS) only was included in the definition of pCR (ypT0/is, ypN0). Between June 1,
2012 and March 17, 2016, 98 patients at 10 centers in Spain were recruited into the METTEN study. DNA sample collection was not included in the original study
design and was added as addendum #3 in April 2012 to re-consent patients for an additional blood draw for germ line DNA extraction. DNA samples from 70 patients
(89% of the full ITT cohort) were subsequently collected and genotyped for SNP rs11212617. (Bottom) Modified CONSORT diagram showing the 70 cases of
HER2-positive BC patients used for the analysis of clinical response analysis to neoadjuvant metformin by the minor allele C of the SNP rs11212617.
of SNP rs11212617 between the non-pCR and pCR cohorts in the
ITT population (Table 1).
Association Between rs11212617 and
Clinical Response
Frequency distributions of SNP rs11212617 were similar between
treatment arms (Table S1). Of the patients in the metformin-
containing arm A, 81.2% of homo or heterozygous patients
for the rs11212617 C allele achieved a pCR, whereas 64.7%
of non-carrier patients did not achieve a pCR (Figure 2, top
panels). Of the patients in the reference arm B, 58.8% of
homo or heterozygous patients for the rs11212617 C allele
and 65% of non-carrier patients achieved a pCR, respectively
(Figure 2, top panels). We employed logistic binary regression
analyses to investigate the association between arm, ATM
rs11212617 genotype, and pCR. In bivariate analysis, we failed
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TABLE 1 | Clinical characteristics of patients at baseline according to pathological
complete response (pCR) status.
Non-pCR (n = 31) pCR (n =48) p-value
Arm 0.335
A 17 (54.8%) 21 (43.8%)
B 14 (45.2%) 27 (56.3%)
SNP rs11212617a 0.214*1
A/A 18 (64.3%) 19 (45.2%)
A/C 6 (21.4%) 17 (40.5%)
C/C 4 (14.3%) 6 (14.3%)
0.118
A/A 18 (64.3%) 19 (45.2%)
A/C, C/C 10 (35.7%) 23 (54.8%)
Age 0.465
<50 20 (64.5%) 27 (56.3%)
≥50 11 (35.5%) 21 (43.8%)
Mean ± SD
(min;max)




Post 11 (35.5%) 20 (41.7%)




64.3 ± 6.9 (48;78) 65.3 ± 10.2 (45.3;89.0) 0.592
Body-mass index 0.179
<25 19 (61.3%) 22 (45.8%)
≥25 (overweight) 12 (38.7%) 26 (54.2%)
Clinical tumor status 0.077*1
cT2 18 (58.1%) 33 (68.8%)
cT3 12 (38.7%) 10 (20.8%)
cT4a 1 (3.2%) 0 (0.0%)
cT4b 0 (0.0%) 4 (8.3%)
cT4d 0 (0.0%) 1 (2.1%)
Clinical nodal stage 0.581*1
cN0 6 (19.4%) 16 (33.3%)
cN1 20 (64.5%) 24 (50.0%)
cN2 1 (3.2%) 2 (4.2%)
cN2a 1 (3.2%) 0 (0.0%)
cN2b 0 (0.0%) 1 (2.1%)
cN3 3 (9.7%) 4 (8.3%)






21 (67.7%) 22 (45.8%)
ER and PgR negative 10 (32.3%) 26 (54.2%)
Tumor gradeb 1.000*1
G1 1 (4.0%) 1 (2.8%)
G2 12 (48.0%) 18 (50.0%)














1.9 ± 2.6 (0.5;13.1) 1.9 ± 1.2 (0.6;5.1) 0.964
*1 Fisher exact test.
aData available for 70 of 79 patients.
bData available for 61 of 79 patients.
TABLE 2 | Expected and observed SNP rs11212617 prevalence (%).
Expecteda Observed
IBSb EURc TSId METTEN trial (n = 70)
ATM rs11212617 % % % n %
A/A 41.1 38.2 51.4 37 52.9
A/C 49.5 47.1 35.5 23 32.9




b IBS, Iberian Population in Spain.
cEUR, European.
dTSI, Tuscany in Italy.
to show predictive capacity of either the arm treatment or
rs11212617 genotype with the probability of achieving pCR
(Table S2). However, we observed a significant relationship
between rs11212617 genotype and the ability of treatment arms
to achieve pCR (ORgenotype×arm = 10.33, 95%CI: 1.29–82.89,
p = 0.028; Table 3). This finding suggested that the direction
and/or intensity of the relationship between rs11212617 genotype
and pCR significantly varied in each treatment arm. Accordingly,
the patients bearing the rs11212617 C allele in the metformin-
containing arm had a significantly higher probability of pCR
(ORA/C,C/C = 7.94, 95%CI: 1.60–39.42, p = 0.011; Figure 2,
bottom panel). Conversely, no association was found between
the presence of the rs11212617 C allele and clinical response
in the (non-metformin) reference arm (ORA/C,C/C = 0.77,
95%CI: 0.20–2.92, p = 0.700; Figure 2, bottom panel).
After additional adjusting for potential confounding tumor
characteristics such as tumor size and hormone receptor (HR)
status, a relationship between the rs11212617 genotype and the
ability of treatment arms to achieve a pCR in patients remained
significant (adjusted ORgenotype×arm = 20.53, 95%CI: 1.97–
213.79, p = 0.011; Table S3). In the metformin-containing arm,
the positive association between the presence of the rs11212617
C allele and pCR remained significant after accounting for
tumor size and HR status (adjusted ORA/C,C/C = 28.88, 95%CI:
2.20–378.73, p = 0.010; Table S4). The lack of association
between the rs11212617 C allele and pCR in the (non-
metformin) reference arm was not altered after adjusting for
these factors (Table S5).
Association Between ATM rs11212617 and
Metabolic Response
A Wilcoxon test was conducted to evaluate whether there
was a significant relationship between the rs11212617 C allele
and the metabolic response to each arm. In the reference
arm, no significant relationship between rs11212617 C allele
and reductions in glucose, insulin, or HOMA-IR index was
evident (Table 4). In the metformin arm, however, there was a
near-significant trend between the rs11212617 C allele and the
metabolic response to metformin in terms of insulin reduction
(p= 0.069; Table 4).
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FIGURE 2 | Association of ATM rs11212617 genotype and pCR by treatment arm. (Top) Rates of pCR stratified by the (C) rs11212617 genotype in patients
randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab (arm A) or equivalent regimen without metformin
(arm B). (Bottom) Relationship between the (C) rs11212617 genotype and the ability of treatment arms to achieve pCR.
DISCUSSION
A significant number of neoadjuvant, adjuvant, and
advanced disease trials are currently ongoing or have
been proposed to elucidate whether metformin, when
used at doses established for diabetes control, has the
potential to be used in preventive and treatment settings
as an adjuvant to established cancer therapeutics. In this
scenario, companion biomarker studies are urgently needed
to define metformin efficacy and refine the tumor types
and/or patient populations that are most likely to benefit from
metformin-containing interventions.
To our knowledge, this is the first prospective study
evaluating the relationship between the ATM SNP rs11212617
C allele, which has been associated with an increased likelihood
of metformin treatment success in T2D (1, 3, 5), and
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the clinical benefit of adding metformin to well-established
neoadjuvant treatment regimens in breast cancer patients.
Logistic regression analyses revealed a significant relationship
between the rs11212617 genotype and the ability of treatment
arms to achieve a pCR. In the metformin-containing arm,
patients bearing the rs11212617 C allele had a significantly
higher probability of pCR. Conversely, no association was found
between rs11212617 and clinical response in the reference
arm. Because greater benefits from HER2-targeted neoadjuvant
treatment in breast cancer are achieved in patients with small
HR-negative tumors compared with patients with large HR-
positive tumors (25), it is noteworthy that the capacity of
the ATM rs11212617 C allele to predict a higher chance of
achieving a pCR in patients treated with neoadjuvant metformin
was not altered after accounting for factors like tumor size
and HR status.
A previous report by Reni et al. (21) failed to observe any
association between the C allele of rs11212617 and the clinical
response to metformin in pancreatic cancer, but a significant
relationship between the highest reduction of fasting plasma
glucose and the CC genotype was observed. Our study suggests
that the presence of the minor C allele of rs11212617 might
associate with a significant improvement in insulin sensitivity in
HER2-positive breast cancer patients subjected to neoadjuvant
metformin in combination with trastuzumab and chemotherapy.
This was evidenced by a near significant reduction of circulating
insulin levels and HOMA-IR index—which fairly correlates with
the insulin sensitivity index calculated using the minimal model
TABLE 3 | Association of the interaction between ATM rs11212617 genotype and
pCR by treatment arm.
Odds ratio (95% CI) p-value
ATM rs11212617 A/A 1
A/C, C/C 0.77 (0.20–2.92) 0.700
Arm B 1
A 0.29 (0.08–1.14) 0.076
Genotype × Arm 10.33 (1.29–82.99) 0.028
approach (26), solely in those patients bearing SNP rs11212617
C allele in the metformin-containing arm despite maintenance of
blood glucose levels.
Limitations of this study are inherent in the design; in
particular, the open-label nature of the study, and a relatively
modest sample size. Further, because a concurrent analysis
of well-characterized breast cancer biomarkers relevant for
the putative mechanism of metformin was not achievable,
it might be argued that the outcome predicted by the
“favorable” C allele could be partially biased. Cancer cells
expressing constitutively active phosphatidylinositol-3 kinase
(PI3K) are proliferative regardless of the absence of insulin,
and they can form dietary restriction (DR)-resistant tumors
in vivo (27). Accordingly, because the binding of insulin to
its receptors activates the PI3K/AKT/mammalian target of
rapamycin (mTOR) signaling cascade, activating mutations in
the PIK3CA oncogene might be expected to determine tumor
response to DR-like pharmacological strategies targeting the
insulin and mTOR pathways (27, 28). In our hands, however,
breast cancer xenografts harboring the insulin-unresponsive,
DR-resistant, PIK3CA-activating mutation H1047R remained
largely sensitive to the anti-tumoral effects of metformin (29).
Given that new groundbreaking research has shown how dietary
approaches such as carb-restricted ketogenic diets can prevent
the systemic glucose-insulin feedback that impairs the efficacy
of PI3K inhibitors (30), our current findings, together with the
ability of metformin to significantly augment the circulating
the levels of the ketone body beta-hydroxybutyrate in the
metformin-containing arm of the METTEN study (manuscript
in preparation), might have a significant impact on the design
of future trials evaluating the potential of combining metformin
with targeted therapy.
In summary, we have genotyped a subset of patients included
in a neoadjuvant breast cancer trial to explore the effect of
rs11212617 variants on the clinical endpoint pCR, a powerful
predictor of long-term outcome of patients with HER2-positive
disease treated with neoadjuvant therapy with or without HER2-
targeted agents (31–33). The present findings, although limited
by the small effect size, suggest that further analyses using a larger
TABLE 4 | Association of ATM rs11212617 genotype with changes in glucose, insulin, and HOMA-IR pre- and post-treatment.
Pre-treatment Post-treatment p-valuea Pre-treatment Post-treatment p-valuea
Arm A n MDb (p25,p75) MD (p25,p75) Arm B n MD (p25,p75) MD (p25,p75)
Glucose Glucose
A/A 17 5.27 (4.99,5.54) 5.38 (5.13,5.66) 0.410 A/A 20 5.14 (4.82,5.30) 5.13 (4.60,5.77) 0.588
A/C,C/C 16 5.26 (4.84,5.43) 5.03 (4.79,5.36) 0.109 A/C,C/C 17 5.30 (4.84,5.50) 5.30 (4.92,5.64) 0.344
Insulin Insulin
A/A 14 4.78 (3.76,6.39) 7.22 (2.73,8.95) 0.245 A/A 9 5.55 (3.59,11.68) 7.85 (4.93,17.60) 0.441
A/C,C/C 8 6.38 (3.56,9.54) 4.39 (2.26,6.75) 0.069 A/C,C/C 10 6.46 (3.82,10.43) 4.27 (3.74,7.21) 0.169
HOMA-IRc HOMA-IR
A/A 14 1.13 (0.97,1.55) 1.51 (0.64,2.10) 0.397 A/A 9 1.10 (0.80,2.79) 1.96 (0.94,5.36) 0.260
A/C,C/C 8 1.54 (0.82,2.25) 0.95 (0.46,1.65) 0.093 A/C,C/C 10 1.45 (0.86,2.61) 1.09 (0.80,1.80) 0.241
aWilcoxon test.
bMD, Median.
cHomeostasis Model Assessment of Insulin Resistance.
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number of breast cancer patients treated with metformin should
verify whether a pharmacogenomic profile including the analysis
of ATM SNP rs11212617 genotype might deserve consideration
as a predictive clinical biomarker to inform the personalized use
of metformin in a cancer setting.
CONCLUSIONS
Association with a significantly augmented pCR rate was
found in metformin-treated breast cancer patients that have a
“favorable” C allele-containing ATM SNP rs11212617 genotype.
Because achievement of pCR is an appropriate surrogate for
significantly improved long-term clinical outcomes in high-
risk breast cancer subtypes (34), future studies validating
this association of favorable ATM rs11212617 genotype with
improvements in relapse-free survival after surgery in the
METTEN study (and retrospective outcome analyses for
other clinical trials) should definitely determine whether the
rs11212617 C allele may lead to actionable modifications for
prospective clinical planning in metformin-based anti-breast
cancer approaches.
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